1.0Future News 24https://futurenews24.comFuture News 24https://futurenews24.com/index.php/author/mridulpahuja20/rich600338<blockquote class="wp-embedded-content" data-secret="gL5AdJ02lm"><a href="https://futurenews24.com/index.php/2026/07/21/s41434-026-00631-3/">rAAV manufacturing price evaluation: Indication-specific price per dose and discount methods</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://futurenews24.com/index.php/2026/07/21/s41434-026-00631-3/embed/#?secret=gL5AdJ02lm" width="600" height="338" title="“rAAV manufacturing price evaluation: Indication-specific price per dose and discount methods” — Future News 24" data-secret="gL5AdJ02lm" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://futurenews24.com/wp-includes/js/wp-embed.min.js </script> https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41434-026-00631-3/MediaObjects/41434_2026_631_Fig1_HTML.png10241024Recombinant adeno-associated virus (rAAV) vectors underpin many approved and late-stage gene therapies, yet manufacturing costs remain a major driver of therapy price. Here, we present the first comprehensive, platform-resolved cost analysis of rAAV production across three industrially relevant suspension platforms: transient transfection, baculovirus infection, and producer cell line (PCL). Using a bottom-up model, we decompose total cost-of-goods (COGs) into upstream, downstream, drug product, and quality control contributions at bioreactor scales from 50 L to 2000 L. We show that, on a per-batch basis, baculovirus infection is the most cost-efficient platform, followed by transient transfection and PCLs however, when costs are normalized to vector titer (cost per 1 × 10¹² vg), the ranking shifts, with transient transfection becoming the lowest-cost platform under the modeled assumptions, followed by baculovirus infection and PCL platforms, underscoring the dominant influence of productivity on unit cost. We identify platform-specific cost drivers—plasmids, transfection reagent, and media in transient transfection; media and perfusion consumables in PCL platforms; and affinity capture chromatography in baculovirus processes—with buffer preparation consistently representing the largest downstream material cost across platforms. We further quantify the impact of process development levers: transfection optimization and perfusion-based intensification reduce cost per dose by up to an order of magnitude, whereas affinity resin reuse and capsid enrichment strategies provide modest, incremental savings. Incorporating indication-specific annual viral genome demand reveals how process optimization and scale-up together reduce batch burden and lower dose cost by up to two orders of magnitude, suggesting the potential for improved supply feasibility, even for high-dose neuromuscular indications, under the modeled assumptions of productivity improvement and process optimization. Together, these results provide a quantitative framework linking platform choice, process scale, and unit operations to rAAV manufacturing COGs.